Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints - Reuters

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

Ads Links by Easy Branches
Play online games for free at games.easybranches.com

Guest Post Services www.easybranches.com/contribute
Rock Used as a Doorstop For Decades Turns Out to Be Worth Over $1 Million - ScienceAlert
NASA Selects Four Commercial Companies to Support Near Space Network - NASA

Retired military weather satellite breaks up - SpaceNews
Giant sloths and mastodons lived with humans for millennia in the Americas, new discoveries suggest - The Boston Globe